The short version of immunomodulatory peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-04. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
=== Binding of SSRIs to SERT protein === The molecular basis for SSRIs function, including their binding mode and molecular mechanism of 5-HT re-uptake inhibition in SERT, is not fully understood and is a matter of debate. Such information is very important for the understanding of essential aspects of the drugs action, ranging from selectivity profile to therapeutic efficacy and the development of new and improved drugs that target the human SERT. The three-dimensional (3D) structure of SERT is not known and has been the main obstacle for elucidation of the structural mechanism of the human SERT. Update: X-ray crystallography data is available as of 2017 it seems (https://www.rcsb.org/structure/6AWO)... Comparative molecular modeling have been used in research to create structural models of human SERT in complex with its ligand but has not given good results because of low phylogenetic and functional similarity between human SERT and available template proteins. However the 3D structure of some bacterial homologous transporters like the leucine transporter (LeuT) is known. The human SERT, NET and DAT are all members of the neurotransmitter:sodium symporter (NSS) protein family. SERT contains approximately 630 amino acids that are predicted to form 12 transmembrane alpha-helixes (TMs) which are connected with intra- and extracellular loops (ILs and ELs).
=== Derivatives === Identified uses for DMPEA includes the following list of agents: 1. Bevantolol. 2. Bisobrin 3. Bometolol 4. Buquiterine 5. Denopamine 6. Dobutamine 7. Dopamine 8. Dopexamine 9. Dramedilol 10. Drotaverine 11. Ecastolol 12. Falipamil 13. Gallopamil 14. Methopholine 15. Mixidine 16. Mefeclorazine 17. Nigellimine [4594-02-9] 18. Nuciferine 19. Papaverine 20. Tetrabenazine 21. Tiapamil 22. Trimethoquinol 23. Veradoline 24. Verapamil.
The Unitized Group Ration – M (UGR-M), formerly the Unitized Group Ration – B (UGR-B), is the successor to the B-ration, and consists of packaged and dehydrated unprepared food intended to be assembled and prepared in a field kitchen. Designed to suit the needs of the U.S. Marine Corps, each UGR-M comes with ingredients that are primarily tailored toward specific recipes but could potentially be used to prepare other dishes. The UGR-M has 7 breakfast menus and 14 lunch/dinner menus. Each meal provides an average of 1,300 kcal. Each UGR-M module contains 50 meals, with each pallet holding 400 meals. UGR-M modules have a minimum shelf life of 18 months at 80 °F (26.6 °C).
Sources: en.wikipedia.org
The liver is the second largest organ (after the skin) and is an accessory digestive gland which plays a role in the body's metabolism. The liver has many functions some of which are important to digestion. The liver can detoxify various metabolites; synthesise proteins and produce biochemicals needed for digestion. It regulates the storage of glycogen which it can form from glucose (glycogenesis). The liver can also synthesise glucose from certain amino acids. Its digestive functions are largely involved with the breaking down of carbohydrates. It also maintains protein metabolism in its synthesis and degradation. In lipid metabolism it synthesises cholesterol. Fats are also produced in the process of lipogenesis. The liver synthesises the bulk of lipoproteins. The liver is located in the upper right quadrant of the abdomen and below the diaphragm to which it is attached at one part, the bare area of the liver. This is to the right of the stomach and it overlies the gall bladder. The liver synthesises bile acids and lecithin to promote the digestion of fat.
The 21st century saw the company return to independence when it was purchased from Diageo by a group of investment firms led by TPG Capital for US$1.5 billion in 2002. The new owners rapidly moved to revitalize and reorganize the company, culminating with the company being taken public in 2006 with a highly successful initial public offering. The firms' strategy for turning the chain around included a new advertising agency and new ad campaigns, a revamped menu strategy, a series of programs designed to revamp individual stores, a new restaurant concept called the BK Whopper Bar, and a new design format called 20/20. These changes successfully re-energized the company, leading to a score of profitable quarters. New owners failed to stop the Great Recession from weakening the company's outlook, even as competitor McDonald's grew. The falling value of Burger King eventually led to TPG and its partners divesting their interest in the chain in a US$3.26 billion sale to 3G Capital of Brazil. Analysts from financial firms UBS and Stifel Nicolaus agreed that 3G would have to invest heavily in the company to help reverse its fortunes. After the deal was completed, the company's stock was removed from the New York Stock Exchange, ending four years as a public company. The delisting of its stock was designed to help the company repair its fundamental business structures and continue working to close the gap with McDonald's without having to worry about pleasing shareholders.
=== Genetics === Genetics plays a major role in fibromyalgia and may explain up to 50% of disease susceptibility. Fibromyalgia is potentially associated with polymorphisms of genes in the serotonergic, dopaminergic and catecholaminergic systems. Several genes have been suggested as candidates for susceptibility to fibromyalgia. These include a coding variation in Huntingtin, SLC6A4, TRPV2, MYT1L, NRXN3, and the 5-HT2A receptor 102T/C polymorphism. The heritability of fibromyalgia is estimated to be higher in patients younger than 50. Nearly all the genes suggested as potential risk factors for fibromyalgia are associated with neurotransmitters and their receptors.
Sources: en.wikipedia.org
=== Iodothyronine deiodinase === Central to human (and vertebrate in general) thyroid hormone metabolism are three iodothyronine deiodinases, with gene symbols DIO1, DIO2, DIO3 in humans. Related proteins have been found in invertebrate chordates, mostly with a selenocystine, though a few have cystine instead.
Diethyl ether could also be mixed with other anesthetic agents such as chloroform to make C.E. mixture, or chloroform and alcohol to make A.C.E. mixture. In the mid-20th century the growing use of electrical cauterization in surgery necessitated a switch to non-flammable anesthesia. In the 21st century, ether is rarely used. The use of flammable ether was displaced by nonflammable fluorinated hydrocarbon anesthetics. Halothane was the first such anesthetic developed and other currently used inhaled anesthetics, such as isoflurane, desflurane, and sevoflurane, are halogenated ethers. Diethyl ether was found to have undesirable side effects, such as post-anesthetic nausea and vomiting. Modern anesthetic agents reduce these side effects.
=== α/β === α/β proteins are a class of structural domains in which the secondary structure is composed of alternating α-helices and β-strands along the backbone. The β-strands are therefore mostly parallel. Common examples include the flavodoxin fold, the TIM barrel and leucine-rich-repeat (LRR) proteins such as ribonuclease inhibitor.
=== Menopausal hormone therapy === CPA is used at low doses in menopausal hormone therapy in combination with an estrogen to provide endometrial protection and treat menopausal symptoms. It is used in menopausal hormone therapy under the brand name Climen, which is a sequential preparation that contains 2 mg estradiol valerate and 1 mg CPA. Climen was the first product for use in menopausal hormone therapy containing CPA to be marketed. It is available in more than 40 countries.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.